BPC-157 Peptide
| BPC-157 Profile Data | |
|---|---|
| Clinical Data | |
| Routes of administration | IM, IV, IP (in animals), oral, subQ |
| Drug class | peptide |
| Pharmacokinetic Data | |
| Elimination half-life | 7.9–30 minutes (rat, IV and IM)[1] |
| Identifiers | |
| CAS Number | 137525-51-0 |
| PubChem CID | 9941957 |
| DrugBank | DB11882 |
| ChemSpider | 8117571 |
| UNII | 8ED8NXK95P |
| ChEMBL | ChEMBL4297358 |
| Chemical and Physical Data | |
| Formula | C62H98N16O22 |
| Molar mass | 1419.556 g·mol−1 |
Development Timeline of BPC-157
- 1989: Researchers in Zagreb, Croatia, successfully isolate a protective protein complex in human gastric juice, giving rise to the name Body Protection Compound (BPC).
- 1992–1993: The scientific team synthesizes a stable 15-amino-acid fragment of the protein—BPC-157 (pentadecapeptide)—and publishes the initial foundational landmark study in the Journal of Physiology, Paris (1993).
- 1994: A major patent (U.S. Patent No. 5,288,708) is granted covering the sequence, extraction, and protective properties of the peptide.
- Mid-1990s – 2000s: Pharmaceutical partnerships begin. BPC-157 enters initial clinical research phases under development codes PL 14736, PL-10, and PLD-116, targeting inflammatory bowel disease (IBD) and ulcerative colitis.
- 2003–2010: Preclinical research expands from gastrointestinal focus into soft-tissue healing. Key papers demonstrate BPC-157’s capacity to accelerate the repair of transected Achilles tendons, ligaments, and muscle tissue in rodent models.
- 2014–2017: Global academic interest grows; independent studies reveal cellular mechanisms, specifically how BPC-157 interacts with nitric oxide (NO) pathways and upregulates VEGFR2 expression to induce angiogenesis (new blood vessel growth).
- 2022: The World Anti-Doping Agency (WADA) officially bans BPC-157 globally for competitive athletes under Section S0 (Unapproved Substances).
- September 2023: The U.S. Food and Drug Administration (FDA) places BPC-157 on the 503A Category 2 Bulk Drug Substances list, effectively restricting compounding pharmacies from legally manufacturing or dispensing the compound.
Scientists Behind BPC-157
Lead Discoverers and Core Authors
- Dr. Predrag Sikirić: Primary inventor, principal investigator, and pharmacologist at the University of Zagreb School of Medicine who led the team that first synthesized and characterized BPC-157.
- Dr. Sven Seiwerth: Lead pathologist at the University of Zagreb and long-time primary scientific collaborator of Dr. Sikirić across almost all core preclinical trials.
- Dr. Rudolf Rucman: Key researcher involved in the peptide synthesis, chemical isolation, and primary patent filings for BPC-157.
- Dr. Marijan Petek: Co-inventor and investigator on early pharmacological studies mapping organ protective mechanisms.
Key Croatian Research Collaborators
- Dr. Branko Turković
- Dr. Marko Banić
- Dr. Stjepan Sever
- Dr. Luka Brcic
- Dr. Slaven Gojković
- Dr. Ivo Rotkvić
- Dr. Zoran Grabarević
- Dr. Mislav Staresinic
- Dr. Robert Rozman: Clinical trial coordinator and patent assignor.
Independent Global Researchers
- Dr. Tze-Cheng Chou: Lead researcher (along with Chung-Hsun Chang and Wen-Chung Tsai) at Chang Gung University, Taiwan, who published seminal independent work demonstrating BPC-157’s effects on human tendon cell migration and growth factor signaling.
- Dr. L. He and Dr. D. Feng: Researchers involved in evaluating animal pharmacokinetics and safety parameters in modern preclinical studies.
Organizations Behind Development of BPC-157
Academic and Technology Transfer Institutions
- University of Zagreb (Croatia): The home academic institution (specifically the Department of Pharmacology and Institute of Pathology) where BPC-157 was discovered, developed, and evaluated through decades of research.
- Yissum Research Development Company: The tech-transfer arm of the Hebrew University of Jerusalem that participated in early patent assignments and research licensing for organoprotective peptide derivatives.
Pharmaceutical Companies & Corporate Ventures
- Diagen d.o.o. (Croatia): The dedicated biopharmaceutical company established to hold primary intellectual property, fund research, and develop BPC-157 under the clinical code PL 14736.
- PLIVA d.d. (Croatia / now Teva Pharmaceutical Industries): Major Croatian pharmaceutical manufacturer that partnered with the Zagreb discovery team to conduct early industrial synthesis, pharmaceutical formulation, and early-phase clinical evaluations.
- Parke-Davis / Warner-Lambert (USA): The American pharmaceutical enterprise (later acquired by Pfizer) that held collaborative research partnerships in the late 1990s evaluating gastrointestinal protective peptides from the Croatian team.
- PharmaCotherapia: A biopharmaceutical venture entity that held rights and pursued clinical trial applications for oral and topical formulations (such as PCO-02) targeting ulcerative colitis.
How Much Does BPC-157 Peptide Cost?
BPC-157 costs $100 to $400 per month out-of-pocket. Pricing varies based on the supplier type (research vendor versus licensed compounding pharmacy), vial size, and whether the fee includes telehealth consultations and injection supplies.
BPC-157 Price Trend 2025 vs 2026
BPC-157 peptide prices decreased by approximately 10% to 15% from 2025 to 2026. The cost of a standard 5mg vial dropped from $30–$45 in 2025 to $25–$35 in 2026, while compounded monthly clinic protocols fell from $150–$350 to $120–$300 due to scaled production and increased telehealth competition.
Here we have listed BPC-157 From Pinnacle Peptide Labs,
1. Pinnacle Peptide Labs’s BPC-157 Peptide Price
At Pinnacle Peptide Labs BPC-157 Price Starts from $89.99 for 10 mg vials
Use the BPC-157 Promo Code and get 15% off
Can You Take BPC-157 Everyday?
Many protocols use daily dosing, but long-term safety data is limited, so cycling or provider guidance is recommended.
What Are The Benefits Of Taking BPC-157?
Studied for tissue repair, gut healing, reduced inflammation, and faster recovery from injuries in animal research.
Can BPC-157 Affect The Heart?
Animal studies suggest possible cardioprotective effects, but human cardiovascular safety data remains limited and unconfirmed.
Can BPC-157 Cause Liver Damage?
No strong evidence of liver damage; some studies suggest protective effects, but human safety data is still lacking.
Can BPC-157 Help With Brain Repair?
Preliminary animal research suggests neuroprotective potential, but robust human studies on brain repair are still lacking.
Disclaimer
This comprehensive document is provided strictly for informational, educational, and scientific research purposes only. The content contained herein does not constitute medical advice, diagnosis, or treatment recommendations. We do not support, endorse, or promote the non-medical, off-label, or unsupervised use of unapproved peptides.
BPC-157 is yet under research. Always consult a licensed, qualified healthcare professional before making any decisions regarding your health, and never substitute the information presented here for professional medical counsel. This article may contain affiliate links, which may result in compensation to the publisher at no additional cost to you.
Comprehensive Clinical and Preclinical Review of BPC-157 (Body Protection Compound-157): Pharmacology, Mechanisms, and Regulatory Status
Pharmacology, Mechanisms, Regulatory Status, and Research Data
1. Introduction and Historical Context of BPC-157 (Body Protection Compound-157)
Body Protection Compound-157 (BPC-157) represents one of the most highly discussed, yet clinically unverified, synthetic peptides in contemporary regenerative medicine and sports science discourse. To understand BPC-157, one must first understand its origins. Unlike many modern synthetic peptides designed purely through computational modeling, BPC-157 is a partial sequence derived from a naturally occurring protein found in human gastric juice. In the early 1990s, a research group led by Professor Predrag Sikirić at the University of Zagreb School of Medicine in Croatia began investigating the protective properties of gastric juice against severe gastrointestinal lesions. They isolated a 15-amino acid sequence that demonstrated remarkable cytoprotective effects. This sequence was subsequently synthesized in the laboratory, giving rise to what is now known as BPC-157. For over three decades, the primary body of research surrounding this compound has been dominated by the Sikirić laboratory group and their collaborators at the University of Zagreb, alongside occasional partnerships with technology transfer entities such as Yissum (the technology transfer company of the Hebrew University of Jerusalem). Their preclinical work has been extensive, claiming “pleiotropic” (multi-system) protective effects ranging from accelerated tendon healing to neuroprotection and the mitigation of inflammatory bowel disease (IBD). However, despite decades of animal research and massive popularity in grey-market and athletic communities, BPC-157 remains firmly in the experimental research phase. As of 2026, it has not been vastly marketed for human use, lacks FDA approval, and has no established safety or efficacy profile in large-scale human populations. This review aims to provide an objective, deeply researched, and highly structured analysis of BPC-157, separating preclinical hypotheses from clinical reality, while strictly adhering to the boundaries of educational and research-oriented discourse.2. Pharmacology and Chemical Profile
To evaluate the potential and limitations of BPC-157, a thorough understanding of its chemical and pharmacological properties is required.2.1 Chemical Structure and Stability
BPC-157 is a synthetic pentadecapeptide, meaning it is composed of exactly 15 amino acids. Its specific amino acid sequence is:2.2 Pharmacokinetics and Bioavailability
It is crucial to note that human pharmacokinetic (PK) data for BPC-157 does not exist. All assumptions regarding absorption, distribution, metabolism, and excretion (ADME) are extrapolated from rodent models. In animal studies, oral administration has shown systemic effects, suggesting some degree of intestinal absorption, though the exact bioavailability percentage remains undefined. Subcutaneous (SC) and intramuscular (IM) administration bypass the gastrointestinal tract, theoretically offering more direct systemic or localized tissue exposure. However, without human PK studies, the half-life, peak plasma concentration (Cmax), and area under the curve (AUC) in humans are entirely speculative.3. Proposed Mechanisms of Action
The purported efficacy of BPC-157 is attributed to a complex, multi-targeted mechanism of action. It is important to emphasize that nearly all mechanistic data is derived from in vitro (cell culture) and in vivo (animal) studies. Human mechanistic confirmation is currently non-existent. The proposed pathways include:3.1 Angiogenesis and VEGF Upregulation
One of the most consistently observed effects of BPC-157 in animal models is the promotion of angiogenesis—the formation of new blood vessels from pre-existing vasculature. This is considered the cornerstone of its proposed wound-healing capabilities. Research suggests BPC-157 upregulates the expression of Vascular Endothelial Growth Factor (VEGF) and interacts with the VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) signaling pathway. By enhancing blood flow to injured or ischemic tissues, the compound theoretically accelerates the delivery of oxygen, nutrients, and reparative cells to the site of damage.3.2 Nitric Oxide (NO) System Modulation
The role of BPC-157 in nitric oxide modulation is complex and represents a dual-action mechanism that is frequently debated in the literature:- Protective NO (eNOS): BPC-157 appears to upregulate endothelial Nitric Oxide Synthase (eNOS), promoting the production of NO that aids in vasodilation, improved microcirculation, and tissue protection.
- Cytotoxic NO (iNOS) Inhibition: Conversely, in states of severe inflammation, inducible Nitric Oxide Synthase (iNOS) produces massive, damaging amounts of NO. Preclinical data suggests BPC-157 may downregulate or counteract this cytotoxic NO overproduction, thereby reducing oxidative stress and tissue damage.
3.3 Growth Factor Upregulation
Beyond VEGF, BPC-157 has been shown in rodent models to stimulate the expression of other critical growth factors involved in tissue repair. This includes Epidermal Growth Factor (EGF) and Fibroblast Growth Factor (FGF). These factors are essential for cellular proliferation, migration, and the synthesis of the extracellular matrix (ECM), which are fundamental steps in closing wounds and repairing connective tissue.3.4 Fibroblast Proliferation and Tendon/Ligament Healing
In specific models of musculoskeletal injury, BPC-157 has demonstrated the ability to promote the outgrowth of fibroblasts (the primary cells responsible for producing collagen). In vitro studies show accelerated fibroblast migration into the wound site, while in vivo studies show improved organization of collagen fibers in healing tendons, leading to greater tensile strength in the repaired tissue compared to untreated controls.3.5 Anti-Inflammatory and Cytoprotective Effects
In models of Inflammatory Bowel Disease (IBD), such as TNBS-induced colitis in rats, BPC-157 has been shown to reduce mucosal inflammation, decrease inflammatory cytokine production, and accelerate the healing of gastric and intestinal ulcers. This is believed to be a downstream effect of its combined angiogenic, NO-modulating, and growth factor-stimulating properties.3.6 Neuroprotection
Emerging, albeit highly preliminary, animal data suggests BPC-157 may have Central Nervous System (CNS) protective effects. Studies in rodent models of Parkinson’s disease, spinal cord injury, and traumatic brain injury have observed reduced neuronal damage and improved functional recovery. The proposed mechanism involves the modulation of dopaminergic and serotonergic systems, alongside the reduction of neuroinflammation, though this remains entirely theoretical for human application.4. Preclinical Research and Published Studies
The vast majority of the scientific literature supporting BPC-157 originates from preclinical models. While the results in these models are often striking, extrapolating rodent data to human physiology requires extreme caution.4.1 Gastrointestinal Healing
The foundational research on BPC-157 focuses on the GI tract. Extensive studies from the University of Zagreb have demonstrated its efficacy in various rodent models of gastrointestinal injury:- Gastric Ulcers: Accelerated healing of ulcers induced by ethanol, aspirin, or indomethacin (NSAIDs).
- Esophagitis and Fistulas: Promotion of healing in experimental esophagitis and the closure of gastrointestinal fistulas in rats.
- Inflammatory Bowel Disease: Significant reduction in colonic damage and inflammation in chemically induced colitis models.
4.2 Musculoskeletal and Connective Tissue Repair
BPC-157 has gained immense popularity in athletic communities due to preclinical data on tendon and ligament repair.- Achilles Tendon Transection: In rat models where the Achilles tendon was completely transected and surgically repaired, the administration of BPC-157 (both locally and systemically) resulted in accelerated healing, improved biomechanical strength, and better organization of collagen fibers at the tendon-to-bone junction.
- Ligament Healing: Similar accelerated recovery has been observed in models of medial collateral ligament (MCL) transection.
- Bone Healing: Some studies suggest enhanced osteoblast activity and accelerated fracture healing, though this data is less robust than the tendon/ligament data.
4.3 Systemic and Organ Protection
The “Body Protection Compound” moniker stems from studies showing systemic protective effects. Rodent studies have indicated potential benefits in:- Mitigating liver damage induced by toxins or ischemia-reperfusion injury.
- Protecting the heart from arrhythmias and ischemic damage.
- Accelerating the healing of severe skin burns and surgical incisions.
4.4 The “Single-Center” Limitation: A Critical Scientific Concern
A major point of contention and scientific skepticism within the broader medical community is the origin of this data. It is a documented fact that greater than 80% of all published BPC-157 research originates from a single research center: the Sikirić laboratory group at the University of Zagreb, Croatia. While the volume of their output is impressive, the lack of independent replication from other major, unbiased academic institutions is a significant red flag in evidence-based medicine. Scientific consensus requires reproducibility. When a single group dominates the literature on a compound, the potential for methodological bias, selective reporting, or unrecognized confounding variables increases. The broader scientific community has repeatedly called for independent, multi-center validation of these extraordinary preclinical claims before any clinical application can be seriously considered.5. Human Clinical Data: The Stark Reality
Despite the expansive preclinical literature and massive grey-market popularity, the human clinical data for BPC-157 is shockingly sparse. As of early 2026, the clinical reality can be summarized as follows:- Only 3 published human pilot studies exist, encompassing fewer than 30 total human subjects combined.
- Zero Randomized Controlled Trials (RCTs) have been published evaluating BPC-157 for any indication.
- No established safe or effective dose exists for humans.
- No Phase 2 or Phase 3 human clinical trials have been completed or published.
5.1 The Cancelled 2015 Phase I Trial
Perhaps the most telling part of BPC-157’s clinical history comes from a Phase I clinical trial registered in 2015. The trial aimed to evaluate BPC-157’s safety and pharmacokinetics in 42 healthy volunteers. The researchers officially registered the trial. However, they later cancelled it and never published the results. Clinical trial registries do not publicly explain why they cancelled the trial. Researchers may cancel trials for many reasons. These can include unexpected safety signals, pharmacokinetic problems, or strategic changes by the sponsor. However, without public documentation, we cannot know the specific reason for this cancellation. The missing trial data leaves a major gap in our understanding of BPC-157’s safety in humans.5.2 Recent Pilot Studies (The <30 Subjects)
The few published human studies are highly limited pilot trials. For example, a notable 2024 pilot study explored the use of BPC-157 via bladder instillation for interstitial cystitis. While the study reported some subjective improvements, it involved a very small sample, lacked a robust placebo control, and could not establish definitive efficacy or long-term safety. In summary, any claim that BPC-157 is “proven to work in humans” is scientifically false. It remains an experimental compound with an unknown risk-to-benefit ratio in human subjects.6. Dosage Protocols: Reported Research and Grey-Market Use
⚠️ STRICT WARNING: It not constitute medical advice. We do not support or promote non-medical advice.
6.1 Reported Administration Routes and Amounts
- Oral Administration: 250 – 500 mcg (0.25 – 0.5 mg), administered once or twice daily. This route is primarily utilized by individuals targeting gastrointestinal issues (e.g., IBD, leaky gut, ulcers), leveraging the peptide’s known stability in gastric juice.
- Subcutaneous (SC) Injection: 200 – 300 mcg, administered once or twice daily. This is the most common route for systemic effects or generalized tissue repair.
- Intramuscular (IM) Injection: 200 – 300 mcg, injected directly into or near the affected muscle or tendon. This is often attempted for localized musculoskeletal injuries, though the scientific validity of “spot injecting” in humans is unproven.
- Bladder Instillation: Site-specific administration. A 2024 pilot study explored this route for interstitial cystitis, but it remains highly experimental and is not a standard protocol.
6.2 Critical Tips and Realities of Unregulated Use
- Legality and Compounding Ban: As of late 2023, the FDA placed BPC-157 on the Category 2 Bulk Drug Substances List. This means the FDA has identified specific, significant safety concerns that preclude its use in compounding. Therefore, BPC-157 cannot be legally compounded or prescribed for human use by licensed pharmacies in the United States.
- Grey-Market Reality: Any product currently marketed as “BPC-157” for human consumption in the US is sourced from the grey market or overseas. These products operate with zero FDA oversight regarding purity, sterility, potency, or safety.
- Unknown Risk Profile: Because no safe dose has been established, users are essentially acting as unmonitored subjects in an uncontrolled experiment.
- Anti-Doping Sanctions: Athletes must be aware that BPC-157 is strictly prohibited under USADA and WADA Rule S0 (Non-Approved Substances), as well as the Department of Defense (DoD) prohibited list. Its use will result in positive drug tests, sanctions, and potential career termination.
- Medical Consultation: It is imperative to consult a physician before considering the use of any unapproved, experimental substance.
7. Safety, Side Effects, and Toxicity Signals
Evaluating the safety profile of BPC-157 requires separating the limited human observations from the theoretical risks identified in animal models.7.1 Human Safety Data
Human safety data is severely limited, encompassing fewer than 30 total published human subjects as of 2026.- Tolerability: In the few small pilot studies conducted, BPC-157 was generally reported as well-tolerated.
- Adverse Events: The most commonly reported issues are mild, localized injection site reactions, including transient pain, redness, and swelling.
- Serious Events: No serious adverse events (SAEs) were reported in the 3 published human pilot studies. However, the sample size is far too small to detect rare or long-term adverse events.
7.2 Animal Study Signals and Theoretical Human Risks
While acute toxicity in rodents appears low, several pharmacological effects observed in animals raise legitimate theoretical concerns for human use:- Pro-Angiogenic Effects and Malignancy Risk: Because BPC-157 promotes the formation of new blood vessels (angiogenesis) via VEGF upregulation, there is a theoretical concern that it could promote the growth of existing, undiagnosed tumors or malignancies. Tumors require angiogenesis to grow and metastasize. While this has not been explicitly confirmed as a direct cause of cancer in humans taking BPC-157, the mechanistic overlap is a significant red flag that cannot be ignored.
- Immunogenicity: The FDA has explicitly cited concerns regarding the potential for immune reactions to synthetic peptides. The human immune system may recognize the synthetic BPC-157 sequence as foreign, potentially leading to the development of anti-drug antibodies (ADAs), which could cause allergic reactions or neutralize the body’s natural, endogenous protective peptides.
- Manufacturing Impurities: Peptides synthesized in unregulated, non-GMP (Good Manufacturing Practice) laboratories often contain impurities. These can include truncated peptide sequences, residual solvents from the synthesis process, or bacterial endotoxins. Injecting or ingesting these impurities poses unknown but potentially severe health risks, including systemic inflammatory responses.
8. Contraindications
Because there is no FDA-approved label for BPC-157, there are no formally established, legally recognized contraindications. However, based on its known pharmacology, mechanism of action, and animal data, the following populations should strictly avoid exposure to this compound:- Active Malignancy or History of Cancer: Due to the pro-angiogenic mechanism of BPC-157, there is a strong theoretical risk that it could accelerate tumor growth or metastasis.
- Pregnancy and Breastfeeding: There is absolutely zero human safety data regarding the use of BPC-157 during pregnancy or lactation. The potential for teratogenic effects (birth defects) or transmission through breast milk is entirely unknown.
- Known Hypersensitivity: While specific allergic reactions to BPC-157 are undocumented, the FDA’s cited concerns regarding peptide immunogenicity suggest that individuals with a history of severe allergic reactions to other peptide therapies should avoid it.
- Athletes Subject to Drug Testing: As noted, BPC-157 is prohibited by USADA, WADA, and the DoD. Any athlete subject to these testing protocols must avoid it entirely to prevent sanctions.
- Patients Receiving Anticoagulants: BPC-157 has demonstrated complex interactions with the hemostatic system and promotes angiogenesis. There is a theoretical risk of interaction with blood thinners (e.g., warfarin, DOACs), potentially altering bleeding or clotting risks.
9. Regulatory and Commercial Landscape
Understanding the regulatory status of BPC-157 is critical for anyone researching this compound.9.1 FDA Status and Trade Names
- No FDA Approval: BPC-157 is not approved by the United States Food and Drug Administration for any indication, human or veterinary.
- No Approved Trade Names: There is no legally marketed, FDA-approved commercial product containing BPC-157 in the USA.
- Compounding Ban (Category 2): In November 2023, the FDA finalized its guidance on compounding, placing BPC-157 on the Category 2 list. This designation applies to bulk drug substances that raise significant safety concerns. It effectively prevents licensed U.S. compounding pharmacies from legally preparing BPC-157 for individual patients.
9.2 The Grey Market
Despite the regulatory bans, BPC-157 is widely available online through “research chemical” vendors and grey-market peptide suppliers. These entities often sell the compound labeled strictly “For Research Use Only” or “Not for Human Consumption” to circumvent FDA regulations. However, the marketing language on these sites frequently implies human benefits, creating a dangerous legal and health grey area. Consumers purchasing these products have no guarantee of the vial’s actual contents, sterility, or concentration.9.3 Claims from Different Companies and Institutions
- Sikiric Laboratory Group (University of Zagreb): This is the primary research group responsible for the vast majority of BPC-157 literature. Their claims, based on decades of rodent studies, include extensive preclinical data demonstrating gastric ulcer healing, tendon/ligament repair, IBD protection, wound healing acceleration, neuroprotection, and systemic organ protection. They claim pleiotropic “body protection” effects across multiple organ systems.
- Independent Scientific Review (Józwiak et al., Pharmaceuticals 2025): A crucial 2025 peer-reviewed review by Józwiak and colleagues provided a much-needed objective summary of BPC-157’s biological activities and probable toxicity. Furthermore, it acknowledged the concerning lack of long-term exposure data and dose-response data in mammals, reinforcing the scientific community’s hesitation to embrace the compound.
10. Research & Published Studies: A Summary
To consolidate the preclinical evidence, the most frequently cited areas of BPC-157 research include:- Gastrointestinal Healing: Extensively studied in rodent models for esophagitis, gastric ulcers, and fistula models. Predrag Sikirić’s group dominated the research at the University of Zagreb since the 1990s.
- Musculoskeletal Repair: Investigated in tendon-to-bone and ligament healing models. Accelerated recovery and improved biomechanical strength have been observed in rat Achilles tendon and ligament transection studies.
- Molecular Pathways: Proposed to interact with the nitric oxide (NO) system (balancing eNOS and iNOS) and VEGFR2-mediated angiogenesis pathways in preclinical models.
- NSAID Protection: Studied for its protective effects against NSAID-induced (e.g., aspirin, indomethacin) gastrointestinal damage in animal models, showing a reduction in mucosal lesions.
11. Frequently Asked Questions (FAQ)
What has BPC-157 been studied for?
Preclinical research has focused primarily on gastrointestinal tissue healing (ulcers, IBD) and musculoskeletal repair (tendon, ligament, and bone healing) in animal models. Secondary research has explored its potential for neuroprotection and systemic organ protection in rodents.
Is BPC-157 FDA approved?
No. BPC-157 is not approved by the FDA for any human or veterinary use. It is not legally available as a prescription medication in the United States and is sold strictly as an unregulated research compound. The FDA has explicitly flagged it as a substance with safety concerns that preclude legal compounding.
How is BPC-157 thought to work?
Proposed mechanisms in the preclinical literature include the modulation of the nitric oxide (NO) system (promoting protective NO while inhibiting cytotoxic NO) and the promotion of angiogenesis (new blood vessel formation) via VEGFR2-related pathways.
Has BPC-157 been tested in humans?
Controlled human trial data is exceptionally limited. As of 2026, only three small pilot studies involving fewer than 30 total human subjects have been published. A planned 2015 Phase I trial in 42 volunteers was cancelled and never published. The overwhelming majority of published evidence comes exclusively from animal and in vitro studies. There are no Phase 2 or Phase 3 randomized controlled trials.
Is it safe to buy BPC-157 from online “research” vendors?
No. Products sold by online research vendors are not subject to FDA oversight, Good Manufacturing Practices (GMP), or independent third-party testing. They carry significant risks of contamination, incorrect dosing, and the presence of toxic synthesis byproducts.
Will BPC-157 cause me to fail a drug test?
May be. Consult with your physician
Final Disclaimer
This content about “BPC-157” is for informational and educational purposes only. The authors and publishers do not support or promote the non-medical use of unapproved peptides. Please note that this article may contain affiliate links, which may result in compensation to the publisher at no additional cost to you.
Discuss BPC-157 in the Peptide Research Forum
Have questions, protocols, or results to share about BPC-157? Join the conversation in our Recovery & Repair Research forum.
Visit the Recovery & Repair Research Forum →Read our research overview: BPC-157 Research Overview: What Has Actually Been Studied? →